Histone deacetylase (HDAC) 6, a class-IIb HDAC, is the only HDAC with two functional deacetylase domains and a zinc-finger motif. HDAC6 was initially described as tubulin deacetylase; however, it also deacetylates other non-histone proteins, including heat-shock protein (Hsp90). Importantly, HDAC6 has an essential role in the aggresomal protein degradation pathway, an alternative system to the proteasome for degradation of polyubiquitinated misfolded/unfolded proteins. Specifically, HDAC6 binds to both polyubiquitinated proteins and dynein motors, thereby acting to recruit protein cargo to dynein motors for transport to aggresomes for lysosomal degradation. 1 We have previously shown that inhibition of both proteasomal and aggresomal protein degradation using bortezomib (BTZ) to inhibit the proteasome and tubacin to inhibit HDAC6, respectively, induces accumulation of polyubiquitinated proteins and significant multiple myeloma (MM) cell stress, followed by apoptosis.
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors Histone deacetylase (HDAC) 6, a class-IIb HDAC, is the only HDAC with two functional deacetylase domains and a zinc-finger motif. HDAC6 was initially described as tubulin deacetylase; however, it also deacetylates other non-histone proteins, including heat-shock protein (Hsp90). Importantly, HDAC6 has an essential role in the aggresomal protein degradation pathway, an alternative system to the proteasome for degradation of polyubiquitinated misfolded/unfolded proteins. Specifically, HDAC6 binds to both polyubiquitinated proteins and dynein motors, thereby acting to recruit protein cargo to dynein motors for transport to aggresomes for lysosomal degradation. 1 We have previously shown that inhibition of both proteasomal and aggresomal protein degradation using bortezomib (BTZ) to inhibit the proteasome and tubacin to inhibit HDAC6, respectively, induces accumulation of polyubiquitinated proteins and significant multiple myeloma (MM) cell stress, followed by apoptosis. 2 More recently, a hydroxamic acid HDAC6-selective inhibitor ACY-1215 combined with BTZ shows significant anti-MM activities in preclinical studies, 3 which have been rapidly translated to phase I/II clinical studies to treat relapsed/refractory MM. 4 Previous studies have also shown that the non-selective HDAC inhibitor vorinostat in combination with BTZ also triggers synergistic cytotoxicity in MM, 5 which has provided the framework for combination clinical trials. 6 Carfilzomib (CFZ) is an epoxyketone proteasome inhibitor, which recently received accelerated Food and Drug Administration approval to treat relapsed refractory MM. 7, 8 In this study, we asked whether HDAC6 inhibitors enhance anti-MM toxicity induced by CFZ. We also delineated differential molecular mechanisms that trigger synergistic MM toxicity triggered by CFZ in combination with either HDAC6-selective or class-I HDAC-selective inhibitors ACY-1215 and MS275 (entinostat), respectively. 9 We first compared the combination effect of the HDAC6-selective inhibitor ACY-1215 with either BTZ or CFZ in MM cell lines. Synergistic cytotoxicity induced by CFZ with ACY-1215 was greater than that by BTZ with ACY-1215 in both RPMI8226 (Figure 1a , upper panel) and MM.1S cells (Figure 1a , lower panel). To further confirm the role of HDAC6 inhibition, we carried out similar combination cytotoxicity experiments using the chemically unrelated HDAC6-selective inhibitor tubastatin-A. Consistent with the ACY-1215 results, tubastatin-A synergistically enhanced both BTZ-and CFZ-induced cytotoxicity. Interestingly, synergistic cytotoxicity, on the basis of combination index (CI) o1, was more significant in RPMI8226 cells than in MM.1S cells (Supplementary Figure 1) . Although BTZ has a remarkable clinical activity in MM, acquired resistance limits its long-term utility. We, therefore, next examined whether HDAC6 inhibition can overcome BTZ resistance in vitro using the BTZ-resistant ANBL (ANBL-R) human MM cell line. Importantly, the synergistic cytotoxicity of ACY-1215 with BTZ was observed even in ANBL-R cells. Similar to Figure 1a , this synergistic cytotoxicity was even more significant with CFZ compared with BTZ ( Figure 1b) . These results suggest that CFZ may have a greater clinical activity in MM than in BTZ when combined with HDAC6 inhibitors.
We and others have shown that non-selective HDAC inhibitors in combination with BTZ trigger synergistic cytotoxicity in MM. 10, 11 These non-selective HDAC inhibitors block not only HDAC6 but also the class-I HDAC activity, 9 and whether synergistic cytotoxicity induced by non-selective HDAC inhibitors with BTZ is due solely to HDAC6 blockade remains unclear. Indeed, we have recently shown that both HDAC3 knockdown and a smallmolecule HDAC3-selective inhibitor BG45 trigger synergistic MM cytotoxicity in combination with BTZ. 12 To address this question, we first examined the cytotoxicity of class-I HDAC-selective inhibitor MS275 in combination with CFZ. MS275 with CFZ induced synergistic cytotoxicity in RPMI8226 cells and additive cytotoxicity in MM.1S cells (Supplementary Figure 2) . Consistent with our studies, MS275 with BTZ also shows significant antitumor activities in other cancer cell types. 13 We next determined whether different molecular mechanisms mediate the synergistic MM cell cytotoxicity of HDAC6 versus class-I HDAC inhibition in combination with CFZ. We first defined the doses of either ACY-1215 (2 mM) or MS275 (2 mM) with CFZ (10 nM) that induced equivalent cytotoxicity (35%) (Supplementary Figure 3 ) and used these culture conditions for subsequent experiments. We have shown that ACY-1215 with BTZ triggers the accumulation of polyubiquitinated proteins associated with cell stress. 3 Although not all polyubiquitinated proteins are degraded by the proteasome, recent studies have shown that proteins specifically linked with lysine (K)48 polyubiquitin are degraded by proteasomes.
14 Our studies showed that CFZ induced Accepted article preview online 22 October 2013; advance online publication, 12 November 2013
Letters to the Editor an accumulation of K48-linked polyubiquitinated proteins and that ACY-1215, but not MS275, markedly enhanced this effect ( Figure 2a ). These results further confirm our previous observations showing involvement of HDAC6 in mediating protein degradation via aggresomes and conversely demonstrating that blocking HDAC6 increases proteasomal protein breakdown. RPMI8226 was the most sensitive MM cell line in response to the combined treatment of HDAC6 inhibitors with proteasome inhibitors. Moreover, our previous studies have shown that RPMI8226 cells constitutively express an XBP-1 spliced form, a marker of unfolded protein response upon endoplasmic reticulum (ER) stress.
15 RPMI8226 cells are therefore under constitutive ER stress at physiological conditions. We consequently hypothesized that combining ACY-1215, but not MS275, with CFZ would further enhance ER stress due to accumulating polyubiquitinated proteins, thereby resulting in an enhanced sensitivity to the combination treatment. Indeed, among MM cell lines, RPMI8226 cells are the most sensitive to ER stressor tunicamycin (Supplementary Figure 4) . Importantly, we observed that downstream molecules of ER stress (p-IRE1a, p-eIF2a, p-JNK and CHOP) were significantly enhanced by the treatment with combination ACY-1215 with CFZ ( Figure 2a) . We further confirmed ER stress triggered by this combination treatment using quantitative PCR to demonstrate enhanced XBP-1 splicing (Figure 2b ). These results indicate that proteasome inhibition with HDAC6 inhibition, but not class-I HDAC inhibition, triggers accumulation of polyubiquitinated proteins followed by ER stress.
We further delineated downstream apoptotic signaling in cells treated with these combinations. Caspases-3 and -7, hallmarks of caspase activation, were cleaved by treatment with ACY-1215 or MS275 in combination with CFZ; however, caspase-9 was more significantly cleaved by ACY-1215 compared with MS275 in RPMI8226 cells. In contrast, caspase-10 was cleaved by CFZ with MS275 but not with ACY-1215. An apoptosis-inducing factor associated with caspase-independent apoptosis was not induced (Figure 2c ). Consistent with RPMI8226 cells, we observed enhanced CHOP and capase-9 cleavage triggered by ACY-1215 with CFZ, as well caspase-8 cleavage triggered by MS275 with CFZ in patient MM cells (Supplementary Figure 5A) . To confirm the significance of caspase cleavage (activation), we used selective caspase inhibitors in the combination treatments. As expected, caspase-9 inhibitor has a more prominent inhibitory effect on cytotoxicity induced by ACY-1215 with CFZ than that by MS275 with CFZ in RPMI8226 cells (Supplementary Figure 5B) and patient MM cells (Supplementary Figures 5C and 5D) .
In summary, we show that BTZ and CFZ trigger significant cytotoxicity in MM cells when combined with selective HDAC6 inhibitors (ACY-1215, tubastatin-A), and that more potent synergistic cytotoxicity of HDAC6 inhibitors was observed with CFZ than with BTZ. We also showed synergistic cytotoxicity triggered by combination CFZ with class-I HDAC inhibitor MS275. Importantly, HDAC6 inhibitor ACY-1215, but not MS275, triggered a marked accumulation of K48-linked polyubiquitinated proteins and ER stress, followed by unfolded protein response. Moreover, CFZ combined with ACY-1215 predominantly triggered intrinsic apoptotic signaling, whereas CFZ with MS275 triggered the extrinsic apoptotic pathway. Our results therefore delineate distinct apoptotic pathways induced by CFZ combined with HDAC6 versus class-I HDAC inhibition, providing the preclinical framework for clinical evaluation of combination therapy to improve patient outcome in MM.
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TH and NR are consultants for Acetylon Pharmaceuticals. KCA is a member of the advisory committees for Onyx, Celgene, Gilead and Sanofi-Aventis and is a scientific founder of Acetylon and Oncopep. RM has financial interests in SHAPE Pharmaceuticals and Acetylon Pharmaceuticals. He is also the inventor on IP licensed to these two entities. RM's interests were V617F mutation of the protein kinase JAK2 is the most prevalent genetic abnormality in the three myeloproliferative neoplasms (MPNs), namely polycythemia vera (PV, 95%), essential thrombocythemia (ET, 60%) and myelofibrosis (MF, 60%). [1] [2] [3] [4] This mutation, which usually affects only one of the JAK2 gene alleles in ET, frequently becomes homozygous in PV and MF. This homozygosity is related to chromosome 9p uniparental disomy (UPD 9p) due to mitotic homologous recombination. It was recently shown that the 46/1 haplotype, defined by four single-nucleotide polymorphisms (SNPs: rs3780367, rs10974944, rs12343867 and rs1159782), was strongly associated with the cis acquisition of JAK2 V617F mutation with complete linkage disequilibrium. [5] [6] [7] As UPD 9p involves most of the chromosome 9, JAK2 V617F and the SNPs that tag 46/1 are converted into homozygosity simultaneously, and the 46/1 SNP allele burden reflects the percentage of JAK2 V617F/V617F cells in 46/1 heterozygous PV patients. The JAK2 V617F allele burden depends on the fraction of cells with a wild type, heterozygous and homozygous genotype. These fractions are usually determined by single-cell analyses. Here, we report that the combined measurement of 46/1 SNPs and JAK2 V617F allele burdens in hematopoietic progenitors and differentiated myeloid compartments allows dissecting the clonal architecture in each cell compartment. This approach can be used to explore the impact of treatments, as demonstrated in patients exposed to alpha-interferon (IFNa).
MODELING JAK2 V617F CLONAL ARCHITECTURE IN PV PATIENTS
We first explored three patients with hemochromatosis, wild-type JAK2 and rs12343867 heterozygosity. Genotyping of 500 singlecell colonies established from sorted CD34 þ CD38 À and CD34 þ CD38 þ progenitors did not identify any rs12343867 homozygous colony (Supplementary Figure S1) , indicating that recombination of the 46/1 haplotype was not a common event.
We selected 9 PV patients heterozygous for rs12343867 allele and JAK2 V617F negative in CD3 þ cells using Taqman allelic discrimination PCR. In all the patients, the rs12343867 and JAK2 V617F allele burdens were measured in sorted CD34 þ cells by both Taqman allelic discrimination PCR and next-generation sequencing (NGS), allowing calculation of the percentage of JAK2 V617F cells. The percentage of cells with a homozygous JAK2 mutation (JAK2 V617F/V617F ) was calculated from the formula: (rs12343867 allele burden À 50%) Â 2, the percentage of cells with a heterozygous JAK2 mutation (JAK2 V617F/WT ) by the formula: (Figure 1) . Interestingly, NGS gave quite similar values than those with allele-specific PCR. Surprisingly, analysis of single-cellderived colonies of patients #5 and #7 progenitors showed more wild-type cells than expected from our PCR-and NGSbased calculations, that is, the JAK2 V617F burden obtained by genotyping CD34
þ -derived colonies was much lower than measured in the CD34 þ cell population. This result was not related to an artifact because experiments could be reproduced at least three times for each patient. One possibility is that a secondary genetic event affects self-renewal capacities of in vitro growth of heterozygous and homozygous JAK2 V617F progenitors and prevents them from growing in short-term culture. This strongly suggests that in vitro cell growth induces a bias in clonal architecture analysis. Nevertheless, our results validate the use of the 46/1 haplotype to construct the JAK2 V617F clonal architecture in CD34 þ cells of PV patients.
JAK2 V617F CLONAL AMPLIFICATION PATTERN IN HEMATOPOIETIC STEM CELLS AND MYELOID COMPARTMENTS
Some evidence suggests that, in MPN patients, the JAK2 V617F clone expands during myeloid differentiation. [8] [9] [10] In mouse models, Jak2 V617F also stimulates the proliferation of hematopoietic stem cells (HSCs) or early progenitors. 11, 12 Calculations obtained from allele-specific PCR and NGS were used with the rs12343867 and JAK2
V617F allele burdens of granulocytes of nine PV patients. Results clearly showed that JAK2 V617F/V617F clone preferentially expands during myeloid differentiation at the expense of WT and JAK2 V617F/WT clones ( Figure 1 ). When JAK2 V617F/V617F clone was absent (patients #3 and #9), JAK2 V617F/WT had no or very little proliferative advantage (Figure 1) 
